Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Index
-
Market Cap
1.23B
Enterprise Value
-7.26M
Income
-294.52M
Sales
0.00M
Book/sh
17.12
Cash/sh
17.38
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
220
IPO
Feb 03, 2023
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
1.00
P/C
0.99
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
11.91
Current Ratio
11.91
Debt/Eq
0.01
LT Debt/Eq
0.00
Option/Short
Yes / Yes
EPS (ttm)
-3.95
EPS next Y
-2.69
EPS next Q
-0.68
EPS this Y
-172.44%
EPS next Y
-23.40%
EPS next 5Y
-
EPS past 3/5Y
-18.36% -40.35%
Sales past 3/5Y
- -
EPS Y/Y TTM
-8.08%
Sales Y/Y TTM
-
EPS Q/Q
-77.07%
Sales Q/Q
-
Insider Own
2.60%
Insider Trans
0.00%
Inst Own
91.85%
Inst Trans
1.90%
ROA
-27.19%
ROE
-29.57%
ROIC
-24.02%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-15.16%
SMA50
-33.78%
SMA200
-61.17%
Trades
Shs Outstand
71.36M
Shs Float
69.51M
52W High
94.90 -81.90%
52W Low
17.34 -0.93%
Volatility
7.11% 6.71%
ATR (14)
1.44
RSI (14)
24.94
Beta
-0.94
Rel Volume
0.36
Avg Volume
1.18M
Volume
336,676
Perf Week
-13.41%
Perf Month
-21.95%
Perf Quarter
-65.01%
Perf Half Y
-55.71%
Perf YTD
-75.30%
Perf Year
-52.95%
Perf 3Y
-68.05%
Perf 5Y
-
Perf 10Y
-
Prev Close
17.36
Price
17.18
Change %
-1.05%
Consensus
Strong Buy
Avg. Price Target
$105.00
Implied Upside
+511.2%
Analysts15incl. previous ratings
Rating Distribution14 Buy · 1 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Apr 27, 2026Initiated
CCanaccord Genuity
Buy$101+487.9%
Mar 26, 2026Initiated
WWolfe Research
Peer Perform
May 02, 2025Initiated
C logoCCitigroup
Buy$60+249.3%
Feb 28, 2025Initiated
WWilliam Blair
Outperform
Jan 08, 2025Initiated
SF logoSStifel
Buy$50+191.1%
Dec 04, 2024Initiated
HH.C. Wainwright
Buy$80+365.7%
Sep 23, 2024Initiated
MS logoMMorgan Stanley
Overweight$118+586.9%
May 21, 2024Initiated
JPM logoJJP Morgan
Overweight$65+278.4%
Apr 09, 2024Initiated
CCantor Fitzgerald
Overweight$65+278.4%
Oct 19, 2023Initiated
JJMP Securities
Mkt Outperform$90+423.9%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BLAS COLL CRESPOOfficerSep 21 '26Proposed Sale35.004,008140,280Sep 21 04:35 PM
Lin XichenCHIEF SCIENTIFIC OFFICERSep 01 '26Option Exercise0.3417,8176,058246,777Sep 02 09:18 PM
Lin XichenCHIEF SCIENTIFIC OFFICERAug 18 '26Option Exercise0.3411,8174,018240,777Aug 19 08:23 PM
Lin XichenCHIEF SCIENTIFIC OFFICERAug 04 '26Option Exercise0.3411,8174,018240,777Aug 05 04:49 PM
Lin XichenCHIEF SCIENTIFIC OFFICERJul 14 '26Option Exercise0.3423,6348,036252,594Jul 15 06:57 PM
Lin XichenCHIEF SCIENTIFIC OFFICERJun 25 '26Option Exercise0.3423,6348,036252,594Jun 29 08:32 PM
XICHEN LINOfficerJun 25 '26Proposed Sale48.1635,5121,710,258Jun 25 04:27 PM
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.
CEO & DirectorDr. Raymond C. Stevens Ph.D.
Co- FounderMr. Jun S. Yoon
Chief Technology OfficerDr. Yingli Ma Ph.D.
Chief Scientific Officer & GM of Structure ShanghaiDr. Xichen Lin Ph.D.
Ph.D.Dr. Blai Coll M.D.